SOMERSET, N.J. – July 9, 2019 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.
This…
Cambridge, UK, 4th July, 2019: We are delighted to announce Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away. Over the years, Sunil has championed EIS Angel investing and biotech therapeutics to generate investment into…
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
Under this new agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable liquid formulation of one of the global pharmaceutical company’s key proprietary products. The new formulation will be stored…
On Thursday 4 July Dr. Fiona Marshall, Global Head of Neuroscience Discovery, MSD visited Newcastle to mark the official launch of The Biosphere.
Located at Newcastle Helix, The Biosphere is a specialist lab facility tailored to commercialisation of life sciences. It provides biology and chemistry laboratories and high-quality office space.
Dr. Fiona Marshall was joined by Cllr Ged Bell, Cabinet Member for Employment and Investment and Pat Ritchie, Chief Executive, Newcastle City Council who used this opportunity to bring the sector together and thank everyone who has…
Cambridge, UK, 08 July 2019: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India. CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,. The aim of the collaboration is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.
PhoreMost…
Cambridge, UK, 8 July 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology. The Phase 1 trial will be the first CAR-…
Artificial Intelligence (AI) and machine learning in healthcare and life sciences holds the promise of reforming the industry. Generating and harnessing mass pools of data, the healthcare and life science industries are particularly primed to profit from the potential of AI, offering the unearthing of hidden insights in a world of unstructured data. Frost and Sullivan predicts that the health AI market, valued at US$600 million in 2014 will reach a high of US$6.2 billion by 2022.
The innovative analytics strategies behind AI and machine learning are increasingly having more impact on all…
AMSBIO reports on the pioneering research published** in a collaborative effort between researchers in the School of Engineering, University of Newcastle and Department of Pharmacology, University of Cambridge, UK that has cited Biotinylated Hyaluronan Binding Protein (biotin-HABP) supplied by the company in its investigation into the cancer resistance of the naked mole-rat (NMR).Hyaluronan (also known as Hyaluronic Acid, or HA) is a glycosaminoglycan with a simple conserved structure. It is widespread in the extracellular matrix, playing many…
Are you attending ON Helix 19? Do you fancy winning one of our wise owls? During the event, if you use our event hashtag (#ONHelix19) you will be automatically entered to win one of our owls!
Terms and ConditionsOne owl to give away on each day.The winner will be chosen at random and must have attended the event.Winner will be contacted by direct message no later 19 July.LinkedIn and Twitter are the elegable social media platforms.
**Please note that the eyes are pins (with backings) so this is not a toy. Best to be used on a desk to spark wise thoughts.**
Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totalling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform.
Oxford, UK, 18thJune, 2019– Oxford Drug Design Limited, a biotechnology company with a proprietary computational and machine learning platform, announced today that CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) has agreed to back their lead in-house discovery…